At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 46 enrolled
Drug / intervention
Adalimumab +1 moredrug
Likely dose
Methotrexate 2.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Concomitant Longitudinal Evaluation of Adalimumab With Methotrexate in the Real World: the CLEAR Study
In Brief
A Phase 3 clinical trial evaluating Adalimumab and Methotrexate for Psoriasis. Completed, enrolled 46 participants.
Detailed Summary
The purpose of this study is to determine the safety and efficacy of the use of the combination therapy adalimumab (ADA) every other week (EOW) with methotrexate (MTX) in suboptimal responders to ADA monotherapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJul 2014
Enrollment StartAug 2014
Primary CompletionMar 2017
TodayJul 2026
First PostedJul 22, 2014
Enrollment StartAug 5, 2014
Primary CompletionMar 17, 2017
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 11.9 years ago
Interventions
Adalimumabdrug
Administered by subcutaneous injection every other week.
Methotrexatedrug
Methotrexate was provided as 2.5 mg tablets for oral administration.